|
Daily Medical Update
Antithrombotic therapy in cardiovascular disease
Sunday, June 07, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Current Problems in Cardiology (2025) - Meta-analysis of randomized trials
Key Findings
- Dual therapy increased cardiovascular death vs OAC alone (OR 1.42; 95% CI 1.05-1.92) without reducing myocardial infarction, ischemic stroke, or systemic embolism.
- Dual therapy increased major bleeding (OR 2.20; 95% CI 1.51-3.22) and major or clinically relevant non-major bleeding (OR 2.30; 95% CI 1.72-3.06).
📋 Practice Implication: For chronic coronary syndrome patients who already need long-term anticoagulation, routine continuation of a single antiplatelet agent appears hard to justify once the coronary disease is stable.
|
The American Journal of Medicine (2025) - Meta-analysis of randomized controlled trials
Key Findings
- OAC monotherapy lowered the composite of cardiovascular death, stroke, myocardial infarction, and major bleeding vs dual therapy (RR 0.68; 95% CI 0.53-0.85).
- Major bleeding (RR 0.49; 95% CI 0.31-0.77) and major or clinically relevant non-major bleeding (RR 0.50; 95% CI 0.37-0.68) were reduced, with similar all-cause death and ischemic events.
📋 Practice Implication: In anticoagulated chronic coronary disease, simplification to monotherapy can be treated as a net-clinical-benefit strategy rather than only a bleeding-avoidance compromise.
|
Thrombosis Research (2026) - Network meta-analysis of randomized trials
Key Findings
- De-escalation reduced ISTH major or clinically relevant non-major bleeding vs DOAC dual therapy (RR 0.50; 95% CI 0.30-0.82), although the estimate was driven by a single trial.
- VKA dual therapy (RR 1.33; 95% CI 1.02-1.72) and VKA triple therapy (RR 1.42; 95% CI 1.21-1.66) increased bleeding vs DOAC dual therapy, while VKA triple therapy increased intracranial hemorrhage (RR 2.95; 95% CI 1.32-6.56).
📋 Practice Implication: After PCI in atrial fibrillation, the practical default should remain DOAC-based regimens with the shortest necessary combination exposure, while VKA-based triple therapy looks progressively less defensible.
|
The Cochrane Database of Systematic Reviews (2025) - Systematic review
Key Findings
- Warfarin and aspirin showed no mortality difference in heart failure with sinus rhythm (21.9% vs 21.9%; RR 1.00; 95% CI 0.89-1.13).
- Warfarin reduced non-fatal cardiovascular events (6.6% vs 8.3%; RR 0.79; 95% CI 0.63-1.00) but increased major bleeding (5.6% vs 2.8%; RR 2.00; 95% CI 1.44-2.78).
📋 Practice Implication: Patients with heart failure who remain in sinus rhythm should not be reflexively managed like atrial fibrillation patients, because any thrombotic gain from warfarin is offset by a clear bleeding penalty and no survival benefit.
|
Annals of Vascular Surgery (2025) - Systematic review and network meta-analysis
Key Findings
- Vitamin K antagonists reduced MACE vs low-dose aspirin after open PAD revascularization (RR 0.70; 95% CI 0.51-0.94) but increased major bleeding (RR 1.88; 95% CI 1.39-2.57).
- Rivaroxaban plus low-dose aspirin showed no clear reduction in MACE (RR 0.82; 95% CI 0.58-1.16) or major adverse limb events (RR 0.91; 95% CI 0.77-1.07) vs aspirin alone.
📋 Practice Implication: Post-revascularization PAD still requires individualized antithrombotic escalation, because stronger regimens can improve ischemic outcomes but the bleeding cost remains substantial and evidence for rivaroxaban-based intensification is not definitive.
|
|
💡
Summary
Across recent cardiovascular antithrombotic meta-analyses, the clearest signal is in chronic coronary syndrome patients who already need long-term oral anticoagulation: dropping routine single-antiplatelet therapy lowers major bleeding and may reduce cardiovascular death without a clear ischemic penalty. Evidence in post-PCI atrial fibrillation also favors DOAC-based de-escalation over VKA-heavy regimens. By contrast, in heart failure with sinus rhythm and after open PAD revascularization, intensified anticoagulation trades modest ischemic benefit for more bleeding, so treatment remains phenotype-specific rather than uniform across cardiovascular disease.
|
|